Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Mar 5;3:336–345. doi: 10.1016/j.toxrep.2016.03.001

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 3 — Photo micrographs (at 10X) of liver sections showing dose dependant toxic changes in response to 14 day consecutive treatment of EGCG. (a) Normal liver parenchyma; (b) fatty change with moderate lobular inflammation (arrow); (c) mildly congested liver (box); (d) mild periportal and mild lobular inflammation (arrow), mild kupfer cell hyperplasia. Mild ballooning degeneration (arrow head), focal acute inflammation; (e) congested liver with very mild periportal inflammation (arrow); (f) moderate periportal and mild lobular inflammation, with fatty change (arrow); (g) congested liver with fatty change (box); (h) congested liver parenchyma with moderate lobular acute inflammation, ballooning degeneration of hepatocytes (arrow), hepatocyte drop out areas (star), kupfer cell proliferation and calcification (acute hepatitis); (i) mild kupfer cell hyperplasia and congestion, mild to moderate periportal inflammation (arrow).